LivaNova Delivers Strategic Roadmap and Long-Range Financial Plan at Investor Day

LONDON--(BUSINESS WIRE)--LivaNova PLC (Nasdaq: LIVN), a market-leading medical technology company, today hosted its 2025 Investor Day and presented its comprehensive strategic roadmap and long-range financial plan.

“We are confident in our ability to deliver on the targets we outlined today. LivaNova’s talented team is focused on a revitalized innovation strategy and operational excellence,” said Vladimir Makatsaria, Chief Executive Officer of LivaNova. “The leadership positions we hold in our Epilepsy and Cardiopulmonary businesses give us a strong foundation that provides predictable growth, margin expansion, and consistent cash generation, allowing us to invest in our future.

“This enables us to grow our leadership positions in our core markets. It also allows us to invest in a transformational pipeline and enter higher-growth markets with attractive margin profiles. This includes Obstructive Sleep Apnea, where we have differentiated technology and compelling clinical data. In addition, Difficult-to-Treat Depression remains an upside option as we continue to pursue coverage with the U.S. Centers for Medicare & Medicaid Services. We believe that LivaNova is well positioned for transformative growth and to deliver long-term value — for patients, customers, colleagues, and shareholders.”

LivaNova’s 2030 financial targets include:

• High-single-digit-plus revenue compound annual growth rate (CAGR)
• Adjusted annual operating margin above 20% over the next three years, targeting high twenties by 2030
• Earnings-per-share CAGR in the low double digits to mid-teens
• Adjusted free cash flow conversion above 80%

The Company has established a pathway to achieve this growth by maximizing its core businesses, scaling Obstructive Sleep Apnea (OSA), and preserving upside in Difficult-to-Treat Depression (DTD). At today’s event, LivaNova highlighted the following:

• Market-leading Cardiopulmonary business operating in a $2 billion global market: LivaNova will capitalize on the market opportunity by pursuing a growth strategy driven by the continued replacement cycle of Essenz™, ongoing market-share gains in consumables enhanced by its next-generation oxygenator (estimated launch 2028), and recurring revenue streams via software and service attachments. These efforts are expected to generate mid-to-high single-digit revenue CAGR as well as adjusted operating margin expansion of more than 300 basis points in Cardiopulmonary.
• Global leadership in Drug-Resistant Epilepsy treatment: In Epilepsy, where the market is significantly underpenetrated, the Company expects continued profitable growth. This will be supported by real-world evidence from the CORE-VNS clinical study, a connected care platform (estimated launch 2026) followed by a Bluetooth-enabled implantable pulse generator (estimated launch 2027), and expanded global access and reimbursement. The Company is targeting mid-single-digit revenue CAGR and adjusted operating income margin expansion of approximately 200 basis points by 2030 in Epilepsy.
• Entrance into a large, underpenetrated OSA market with its differentiated proximal hypoglossal nerve stimulation (p-HGNS) technology: The Company’s robust clinical evidence, including newly released data from its PolySync Algorithm™, and a differentiated technology from alternative therapies to treat more challenging patients, such as those with high body mass index and complete concentric collapse, give LivaNova confidence in its capacity to address these needs in this market. PolySync is an advanced multi-contact titration algorithm that utilizes the technology’s six-electrode design to provide a more targeted nerve activation and enable an even greater patient response. Following approval by the U.S. Food and Drug Administration, the Company intends to commercialize its OSA product independently in 2027. By doing so, it will retain full control over pricing, positioning, and customer relationships to maximize long-term value creation. The Company will leverage its proven Neuromodulation infrastructure to scale efficiently with a disciplined, milestone-based investment approach. OSA is projected to generate $200 million to $400 million in revenue by 2030 and adjusted operating income margin of greater than 25%. The Company expects the OSA business to be break-even by 2029.
• DTD coverage reconsideration with U.S. Centers for Medicare & Medicaid Services (CMS): While DTD is not included in the Company’s long-range financial projections given the pending CMS coverage reconsideration, it represents significant upside optionality. DTD is a strategic extension of its Neuromodulation platform and will create meaningful value if CMS coverage is secured.

Webcast Replay

The presentation and webcast replay of today’s investor event will be available within 24 hours at www.livanova.com/events.

About LivaNova

LivaNova PLC is a global medical technology company built on nearly five decades of experience and a vision to change the trajectory of lives for a new day. Through ingenious medical solutions in select neurological and cardiac conditions, LivaNova strives to ignite patient turnarounds. Headquartered in London, with approximately 3,000 employees and a presence in more than 100 countries, LivaNova serves patients, healthcare professionals, and healthcare systems worldwide. For more information, please visit www.livanova.com.

Safe Harbor Statement

This news release contains “forward-looking statements” concerning the Company’s goals, beliefs, targets, expectations, intentions, strategies, objectives, plans, projections, underlying assumptions, and other statements that are not necessarily based on historical facts. These statements include, but are not limited to, statements regarding the Company’s strategic roadmap and long-range financial plan. Actual events may differ materially from those indicated in our forward-looking statements as a result of various factors, including those factors set forth in Item 1A of the Company’s most recent Annual Report on Form 10-K, as supplemented by any risk factors contained in Quarterly Reports on Form 10-Q and Current Reports on Form 8-K. LivaNova undertakes no obligation to update the information contained in this press release to reflect subsequently occurring events or circumstances.